---
document_datetime: 2025-12-15 09:29:33
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/repatha-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: repatha-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.9618692
conversion_datetime: 2026-01-03 12:28:33.917929
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Repatha

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific information after authorisation (archive).

| Applicationnumber    | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|----------------------|----------------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation typeIA_IN/ | B.II.e.6 Change in any part of the (primary) | 12/12/2025                          |                                          | SmPC,                           |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000316562                     | packaging material not in contact with the finished product formulation(such as colour of flip-off caps, colour code rings on ampoules,changeofneedleshield(different plastic used))-B.1I.e.6.a Change that affects the product information - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |     | Labelling and PL   |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------|
| Variation type IB / EMA/VR/0000280756 | This was an application for a group of variationsfollowing aworksharingprocedure accordingtoArticle20ofCommission Regulation(EC)No 1234/2008. B.I.a.1Changeinthemanufacturerofa startingmaterial/reagent/intermediateused in themanufacturingprocessof the active substanceorchangeinthemanufacturer (including where relevant quality control testing sites)ofthe active substance,where noPh.Eur.Certificate ofSuitability ispart of the approved dossier-B.I.a.1.f Changes to quality control testing arrangements for the activesubstance-replacementor addition of a site where batch control/testing takes place - Accepted B.II.b.2Change to importer,batchrelease arrangements and quality control testing of the finished product-B.I1.b.2.a Replacementoradditionofasitewhere batch control/testing takes place - Accepted | 04/09/2025 | N/A |                    |

<div style=\"page-break-after: always\"></div>

| Variation type IA / EMA/VR/0000288203   | B.II.e.6 Change in any part of the (primary) packaging material not in contact with the finished product formulation(such as colour of flip-off caps, colour code rings on ampoules,changeofneedleshield(different plastic used))-B.1I.e.6.b Change that does notaffecttheproductinformation-Refused                                                                                      | 29/07/2025   | N/A   |
|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| Variation type II / EMA/VR/0000258222   | B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.c The change refers to a biological / immunologicalsubstanceoruseofa differentchemicallyderivedsubstanceinthe manufactureofabiological/immunological substance,which may have a significant impact on the quality, safety and efficacy of the medicinal product and is not related to a protocol -Accepted | 24/07/2025   | N/A   |